Case report: Multi-organ injuries induced by tislelizumab
The use of immune checkpoint inhibitors (ICIs) often develops immune-related adverse events (irAEs). However, irAEs-induced multi-organ injuries remain a rare event. We herein report a case of multi-organ injuries induced by tislelizumab in a lung squamous cell carcinoma (LUSC) patient. A 68-year-ol...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1508293/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542329287737344 |
|---|---|
| author | Man Yuan Man Yuan Ning Han Ning Han Li Shu Libo Yan Libo Yan Hong Tang Hong Tang |
| author_facet | Man Yuan Man Yuan Ning Han Ning Han Li Shu Libo Yan Libo Yan Hong Tang Hong Tang |
| author_sort | Man Yuan |
| collection | DOAJ |
| description | The use of immune checkpoint inhibitors (ICIs) often develops immune-related adverse events (irAEs). However, irAEs-induced multi-organ injuries remain a rare event. We herein report a case of multi-organ injuries induced by tislelizumab in a lung squamous cell carcinoma (LUSC) patient. A 68-year-old man had undergone neoadjuvant chemotherapy with paclitaxel, carboplatin, and tislelizumab. He presented with a 1-month history of nausea and poor appetite after the second dose of therapy. During investigations, rhabdomyolysis, liver, kidney, and thyroid damage were detected. After multi-disciplinary consultation, multi-organ injuries related to ICIs (striated muscle, liver, kidney, and thyroid) were considered to result from cumulated irAEs induced by tislelizumab. The patient was treated with levothyroxine, methylprednisolone, intravenous immunoglobulins, and continuous renal replacement therapy. After treatment, the patient recovered and was discharged from the hospital. The patient presented with multiple organ damage, not single immunity treatment adverse reactions, relatively rare. In clinical work, irAEs are likely not a single-system organ disorder and many kinds of attention need to be combined with the risk of multi-system damage. |
| format | Article |
| id | doaj-art-b49738c559204072802d62e018b72b2c |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-b49738c559204072802d62e018b72b2c2025-02-04T06:32:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15082931508293Case report: Multi-organ injuries induced by tislelizumabMan Yuan0Man Yuan1Ning Han2Ning Han3Li Shu4Libo Yan5Libo Yan6Hong Tang7Hong Tang8Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, ChinaDepartment of Infectious Diseases, Suining Central Hospital, Suining, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, ChinaDivision of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, ChinaThe use of immune checkpoint inhibitors (ICIs) often develops immune-related adverse events (irAEs). However, irAEs-induced multi-organ injuries remain a rare event. We herein report a case of multi-organ injuries induced by tislelizumab in a lung squamous cell carcinoma (LUSC) patient. A 68-year-old man had undergone neoadjuvant chemotherapy with paclitaxel, carboplatin, and tislelizumab. He presented with a 1-month history of nausea and poor appetite after the second dose of therapy. During investigations, rhabdomyolysis, liver, kidney, and thyroid damage were detected. After multi-disciplinary consultation, multi-organ injuries related to ICIs (striated muscle, liver, kidney, and thyroid) were considered to result from cumulated irAEs induced by tislelizumab. The patient was treated with levothyroxine, methylprednisolone, intravenous immunoglobulins, and continuous renal replacement therapy. After treatment, the patient recovered and was discharged from the hospital. The patient presented with multiple organ damage, not single immunity treatment adverse reactions, relatively rare. In clinical work, irAEs are likely not a single-system organ disorder and many kinds of attention need to be combined with the risk of multi-system damage.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1508293/fulllung squamous cell carcinomaimmune-related adverse eventsimmune checkpoint inhibitorstislelizumabmulti-organ injuriescase report |
| spellingShingle | Man Yuan Man Yuan Ning Han Ning Han Li Shu Libo Yan Libo Yan Hong Tang Hong Tang Case report: Multi-organ injuries induced by tislelizumab Frontiers in Immunology lung squamous cell carcinoma immune-related adverse events immune checkpoint inhibitors tislelizumab multi-organ injuries case report |
| title | Case report: Multi-organ injuries induced by tislelizumab |
| title_full | Case report: Multi-organ injuries induced by tislelizumab |
| title_fullStr | Case report: Multi-organ injuries induced by tislelizumab |
| title_full_unstemmed | Case report: Multi-organ injuries induced by tislelizumab |
| title_short | Case report: Multi-organ injuries induced by tislelizumab |
| title_sort | case report multi organ injuries induced by tislelizumab |
| topic | lung squamous cell carcinoma immune-related adverse events immune checkpoint inhibitors tislelizumab multi-organ injuries case report |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1508293/full |
| work_keys_str_mv | AT manyuan casereportmultiorganinjuriesinducedbytislelizumab AT manyuan casereportmultiorganinjuriesinducedbytislelizumab AT ninghan casereportmultiorganinjuriesinducedbytislelizumab AT ninghan casereportmultiorganinjuriesinducedbytislelizumab AT lishu casereportmultiorganinjuriesinducedbytislelizumab AT liboyan casereportmultiorganinjuriesinducedbytislelizumab AT liboyan casereportmultiorganinjuriesinducedbytislelizumab AT hongtang casereportmultiorganinjuriesinducedbytislelizumab AT hongtang casereportmultiorganinjuriesinducedbytislelizumab |